Cargando…

Subtyping of metastatic breast cancer based on plasma circulating tumor DNA alterations: An observational, multicentre platform study

BACKGROUND: After multiple lines of therapies, no guideline or consensus is currently available for the treatment of patients with metastatic breast cancer. This study aims to evaluate the efficacy of a novel re-subtyping and treatment strategy based on ctDNA alterations. METHODS: This observational...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Zhe-Yu, Tang, Yu, Liu, Liping, Xie, Ning, Tian, Can, Liu, Binliang, Zou, Lixin, Zhou, Wei, Wang, Yikai, Xia, Xuefeng, Ouyang, Quchang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304912/ https://www.ncbi.nlm.nih.gov/pubmed/35875816 http://dx.doi.org/10.1016/j.eclinm.2022.101567

Ejemplares similares

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC
por: Tang, Yu, et al.
Publicado: (2022)

Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer
por: Zhou, Dabo, et al.
Publicado: (2019)

Corrigendum to “Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer” [Translational Oncology (2019) 12, 764–774]
por: Zhou, Dabo, et al.
Publicado: (2021)

Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance
por: Hu, Zhe-Yu, et al.
Publicado: (2018)

Germline PALB2 Mutations in Cancers and Its Distinction From Somatic PALB2 Mutations in Breast Cancers
por: Hu, Zhe-Yu, et al.
Publicado: (2020)

Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
por: Hu, Zhe-Yu, et al.
Publicado: (2023)

The prognosis and risk factors for capecitabine maintenance treatment in metastatic breast cancer: a retrospective comparative cohort study
por: Tian, Can, et al.
Publicado: (2022)

Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients
por: Liu, Jingyu, et al.
Publicado: (2019)

Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody
por: Liu, Binliang, et al.
Publicado: (2023)

PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies
por: Tang, Yu, et al.
Publicado: (2020)

Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report
por: Xie, Ning, et al.
Publicado: (2021)

FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients
por: Xie, Ning, et al.
Publicado: (2020)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

Impact of surgical management of primary tumors in stage IV breast cancer patients: a retrospective observational study based on SEER database
por: Xie, Ning, et al.
Publicado: (2022)

Artificial intelligence scale-invariant feature transform algorithm-based system to improve the calculation accuracy of Ki-67 index in invasive breast cancer: a multicenter retrospective study
por: Xie, Ning, et al.
Publicado: (2022)

Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer
por: Bando, Hideaki, et al.
Publicado: (2019)

Correction: A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer
por: Bando, Hideaki, et al.
Publicado: (2020)

Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
por: Chen, Qitong, et al.
Publicado: (2020)

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
por: Chen, Qitong, et al.
Publicado: (2021)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
por: Turner, Nicholas C, et al.
Publicado: (2020)

A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer
por: Li, Yi, et al.
Publicado: (2021)

Polarization-Independent Circulator Based on Composite Rod of Ferrite and Plasma in Photonic Crystal Structure
por: Lin, Mi, et al.
Publicado: (2021)

Autonomic function and motor subtypes in Parkinson’s disease: a multicentre cross-sectional study
por: Gu, Si-Chun, et al.
Publicado: (2023)

Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial
por: Liu, Yin, et al.
Publicado: (2023)

Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
por: Zhang, Qingyuan, et al.
Publicado: (2022)

Circulating tumor DNA analysis of metastatic renal cell carcinoma
por: Zhang, Jingbo, et al.
Publicado: (2021)

Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer
por: Guan, Xiuwen, et al.
Publicado: (2021)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
por: Peeters, D J E, et al.
Publicado: (2014)

HER2-positive double primary tumor of gastric and breast cancer occur synchronously in a patient: A case report
por: OUYANG, QUCHANG, et al.
Publicado: (2016)

Circulating Endocannabinoids in Canine Multicentric Lymphoma Patients
por: Hay, Jennifer K., et al.
Publicado: (2022)

Prognostic Significance of Pretreatment Plasma D-dimer Levels in EGFR-Positive Advanced Non-Small Cell Lung Cancer Patients Receiving Osimertinib: A Multicentre Retrospective Study
por: Liu, Qianfei, et al.
Publicado: (2023)

Synchronous multicentric glioblastoma with PNET and O subtypes: Possible pathogenesis
por: Wan, Kai Rui, et al.
Publicado: (2014)

Hepatitis C virus genotypes and subtypes circulating in Mainland China
por: Chen, Ying, et al.
Publicado: (2017)

Evaluation of titanium mesh cranioplasty and polyetheretherketone cranioplasty: protocol for a multicentre, assessor-blinded, randomised controlled trial
por: Yang, Jingguo, et al.
Publicado: (2019)

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
por: Ma, Fei, et al.
Publicado: (2023)

Plasma Circulating Tumor Epstein–Barr Virus for the Surveillance of Cancer Progression in Bone-Only Metastatic Nasopharyngeal Carcinoma
por: Liu, Guo-Ying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tlo6m05oj9dbrm8ct9pk7kheci